Fludrocortisone : interactions médicamenteuses

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

At the primary analysis, increased incidences of fractures (28.6% vs 11.4%) and deaths (38.5% vs 35.5%) have been observed in patients who received abiraterone acetate plus a corticosteroid in combination with radium Ra 223 dichloride compared to patients who received placebo in combination with abiraterone acetate plus a corticosteroid. (notice Abiratérone, Mises en garde et précautions)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

…Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics • Corticosteroids • Theophylline Epinephrine should not be used to counteract circulatory collapse or hypotension caused by phenothiazines, as a reversal of the pressor effects of epinephrine… (notice Adrénaline, Interactions médicamenteuses)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Use of a LABA, including arformoterol tartrate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma. (notice Arformotérol, Contre-indications)

Coadministration of fluticasone propionate and REYATAZ with ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects [see Warnings and Precautions (5.1) ] . (notice Atazanavir, Interactions médicamenteuses)

Withhold INLYTA and avelumab or pembrolizumab, initiate corticosteroid therapy as needed, and/or permanently discontinue the combination for severe or life-threatening hepatotoxicity. (notice Axitinib, Mises en garde et précautions)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Triple combination of candesartan cilexetil with an ACE-inhibitor and a mineralocorticoid receptor antagonist is generally not recommended. (notice Candésartan, Interactions médicamenteuses)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Severe hypersensitivity reactions characterized by generalized rash/erythema, hypotension and/or bronchospasm, or fatal anaphylaxis, have been reported in patients premedicated with 3 days of corticosteroids. (notice Docétaxel, Mises en garde et précautions)

…(5.7) , Drug Interactions (7) , and Clinical Pharmacology (12.3) ]: Anticonvulsants: carbamazepine, oxcarbazepine, phenobarbital, phenytoin Antimycobacterials: rifampin, rifapentine Glucocorticoid (systemic): dexamethasone (more than a single-dose) Herbal Products: St John's wort ( Hypericum perforatum ) Proton Pump Inhibitors: e.g., dexlansoprazole, esomeprazole,… (notice Emtricitabine, rilpivirine et ténofovir, Contre-indications)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Use of a LABA, including formoterol fumarate inhalation solution, without an inhaled corticosteroid is contraindicated in patients with asthma [see Warnings and Precautions (5.1) ]. (notice Formotérol, Contre-indications)

Coadministration of fluticasone and fosamprenavir calcium/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Fosamprénavir, Interactions médicamenteuses)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Fluticasone: Coadministration of fluticasone propionate and ketoconazole is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects. (notice Kétoconazole, Interactions médicamenteuses)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Moreover, cholesterol and other products of the cholesterol biosynthesis pathway are essential components for fetal development, including synthesis of steroids and cell membranes. (notice Lovastatine, Contre-indications)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

WARNING: TERMINATION OF PREGNANCY Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. (notice Mifépristone, Mise en garde encadrée)

If shock, severe trauma or infection occurs or develops, temporarily discontinue LYSODREN and administer exogenous steroids. (notice Mitotane, Mise en garde encadrée)

None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (notice Moexipril, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

…2 , Drug Interactions (7.3) ] ) • Immunosuppressants: voclosporin • Microsomal triglyceride transfer protein inhibitor: lomitapide • Migraine medications: eletriptan, ubrogepant • Mineralocorticoid receptor antagonists: finerenone • Non-opioid analgesic (selective blocker of Na v 1.8 sodium channels): suzetrigine • Opioid antagonists: naloxegol • PDE5 inhibitor:… (notice Nirmatrelvir et ritonavir, Contre-indications)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Antimycobacterials Rifampin Rifapentine Glucocorticoid (systemic) Dexamethasone (more than a single-dose treatment) Herbal Products St. (notice Rilpivirine, Contre-indications)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (notice Salmétérol, Mise en garde encadrée)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Intervention: Carefully adjust glucocorticoid dosing in pediatric patients receiving glucocorticoid treatments to avoid both hypoadrenalism and an inhibitory effect on growth. (notice Somatropine, Interactions médicamenteuses)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Two of the four cases were life-threatening and resolved without treatment or with medication (corticosteroids). (notice Trandolapril, Mises en garde)

At first signs or symptoms of this syndrome, immediately initiate high-dose corticosteroid therapy and hemodynamic monitoring until resolution of signs and symptoms. (notice Trétinoïne, Mise en garde encadrée)

If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. (notice Trioxyde d'arsenic, Mise en garde encadrée)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (notice Uméclidinium et vilantérol, Contre-indications)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Chicken pox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. (notice Fludrocortisone, Mises en garde)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide alendronique, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

…osteonecrosis of the jaw include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting… (notice Acide ibandronique, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, anti-platelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs), smoking, use of alcohol, older age, and poor general health status. (notice Acide méfénamique, Mises en garde et précautions)

Many of these patients were also receiving chemotherapy and corticosteroids, which may be risk factors for ONJ. (notice Acide pamidronique, Mises en garde et précautions)

…the jaw include invasive dental procedures (for example, tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (for example, chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (for example, periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection,… (notice Acide risédronique, Mises en garde et précautions)

Oral Contraceptive Steroids Administration of a single-dose of ethinyloestradiol (50 mcg)/levonorgestrel (250 mcg) to 6 women on valproate (200 mg BID) therapy for 2 months did not reveal any pharmacokinetic interaction. (notice Acide valproïque, Interactions médicamenteuses)

A dental examination with appropriate preventive dentistry should be considered prior to treatment with bisphosphonates in patients with a history of concomitant risk factors (e.g., cancer, chemotherapy, angiogenesis inhibitors, radiotherapy, corticosteroids, poor oral hygiene, preexisting dental disease or infection, anemia, coagulopathy). (notice Acide zolédronique, Mises en garde et précautions)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (notice Aclidinium, Interactions médicamenteuses)

Patients receiving concomitant corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs) or anti-angiogenic agents, or patients with increasing age or who have an underlying history of gastrointestinal ulceration, underlying diverticular disease or bowel metastases may be at increased risk of perforation. (notice Afatinib, Mises en garde et précautions)

Risk of Neurologic Symptoms: Neurocysticercosis patients may experience cerebral hypertensive episodes, seizures or focal neurologic deficits after initiation of therapy; begin appropriate steroid and anticonvulsant therapy. (notice Albendazole, Mises en garde et précautions)

Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (notice Aliskirène, Mises en garde et précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (notice Alpélisib, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Aspirin — increased ulcerogenic effect; decreased pharmacologic effect of aspirin. (notice Fludrocortisone, Interactions médicamenteuses)

Aspirin — increased ulcerogenic effect; decreased pharmacologic effect of aspirin. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Although QVAR REDIHALER may provide control of asthmatic symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid that is necessary for coping with these emergencies. (notice Béclométasone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Belladone et opium, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (notice Bendamustine, Mises en garde et précautions)

• Reduction in Corticosteroid Dosage: Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with FASENRA. (notice Benralizumab, Mises en garde et précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) ↓ lenacapavir (dexamethasone) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (notice Bortézomib, Mises en garde et précautions)

Although PULMICORT FLEXHALER may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. (notice Budésonide, Mises en garde et précautions)

In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of budesonide and formoterol fumarate dihydrate with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Budésonide et formotérol, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Buprénorphine et naloxone, Mises en garde et précautions)

…risk of seizure: concomitant use of other medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse… (notice Bupropion, Mises en garde et précautions)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

Aspirin — increased ulcerogenic effect; decreased pharmacologic effect of aspirin. (notice Fludrocortisone, Interactions médicamenteuses)

Aspirin — increased ulcerogenic effect; decreased pharmacologic effect of aspirin. (notice Fludrocortisone, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Butorphanol, Mises en garde)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

High concentrations of cefoxitin in the urine may interfere with measurement of urinary 17-hydroxy-corticosteroids by the Porter-Silber reaction, and produce false increases of modest degree in the levels reported. (notice Céfoxitine, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants; or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Célécoxib, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Although ALVESCO may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. (notice Ciclésonide, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ciprofloxacine, Mises en garde et précautions)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Plasma cholinesterase activity may be decreased by chronic administration of certain monoamine oxidase inhibitors, oral contraceptives, glucocorticoids, antimyasthenics (neostigmine), cyclophosphamide, and possibly thiotepa. (notice Cocaïne, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Codéine, Mises en garde et précautions)

These reactions include reversible corneal toxicity, and hemorrhagic conjunctivitis, which may be prevented or diminished by prophylaxis with a local corticosteroid eye drop; cerebral and cerebellar dysfunction, including personality changes, somnolence and coma, usually reversible; severe gastrointestinal ulceration, including pneumatosis cystoides intestinalis… (notice Cytarabine, Mises en garde)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Eosinophilic pneumonia: Discontinue Daptomycin for Injection and consider treatment with systemic steroids. (notice Daptomycine, Mises en garde et précautions)

Corticosteroids: dexamethasone (systemic) ↓ darunavir Co-administration of PREZISTA/ritonavir with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to darunavir. (notice Darunavir, Interactions médicamenteuses)

Corticosteroids: dexamethasone (systemic) Corticosteroids primarily metabolized by CYP3A: e.g. betamethasone budesonide ciclesonide fluticasone methylprednisolone mometasone triamcinolone ↓ darunavir ↓ cobicistat ↑ corticosteroids Co-administration with systemic dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic… (notice Darunavir et cobicistat, Interactions médicamenteuses)

The risk of GI hemorrhage may be increased when administering Exjade in combination with drugs that have ulcerogenic or hemorrhagic potential, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, oral bisphosphonates, or anticoagulants. (notice Déférasirox, Mises en garde et précautions)

Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections. (notice Dénosumab, Mises en garde et précautions)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Diclofénac et misoprostol, Mises en garde et précautions)

Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. (notice Dicyclovérine, Interactions médicamenteuses)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Digitalis glycosides — enhanced possibility of arrhythmias or digitalis toxicity associated with hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Eosinophilic Conditions: Be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, kidney injury and/or neuropathy, especially upon reduction of oral corticosteroids. (notice Dupilumab, Mises en garde et précautions)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Although other risk factors were present in some cases (such as corticosteroid use, exposure to radiation), a possible risk attributable to treatment with ivacaftor cannot be excluded. (notice Élexacaftor, tézacaftor et ivacaftor, Mises en garde et précautions)

Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↓ elvitegravir ↓ cobicistat ↑ corticosteroids Coadministration with oral dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to elvitegravir. (notice Elvitégravir, cobicistat, emtricitabine et ténofovir, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Patients receiving concomitant anti-angiogenic agents, corticosteroids, NSAIDs, or taxane-based chemotherapy, or who have prior history of peptic ulceration or diverticular disease may be at increased risk of perforation [see Adverse Reactions (6.1 , 6.2) ]. (notice Erlotinib, Mises en garde et précautions)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Étodolac, Mises en garde)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Corticosteroid : dexamethasone (systemic) ↓ etravirine Systemic dexamethasone induces CYP3A and can decrease etravirine plasma concentrations. (notice Étravirine, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Fénoprofène, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Fentanyl, Mises en garde et précautions)

Pregnancy As with other corticosteroids, flunisolide has been shown to be teratogenic and fetotoxic in rabbits and rats at oral doses of 40 and 200 mcg/kg/day, respectively (approximately 2 and 4 times, respectively, the maximum recommended daily intranasal dose in adults on a mg/m 2 basis). (notice Flunisolide, Précautions)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic absorption of topical corticosteroids. (notice Fluocinonide, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking, use of alcohol, older age, and poor general health status. (notice Flurbiprofène, Mises en garde et précautions)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Although Fluticasone Propionate DISKUS may control asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies. (notice Fluticasone, Mises en garde et précautions)

In this situation, the patient requires immediate reevaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of Fluticasone Propionate/Salmeterol MDPI with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. (notice Fluticasone et salmétérol, Mises en garde et précautions)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Other Corticosteroids, doxycycline, estrogens, furosemide, oral contraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Anticoagulants Apixaban, dabigatran, edoxaban, rivaroxaban Antiepileptic drugs The effect of phenytoin on phenobarbital, valproic acid and sodium valproate serum levels… (notice Fosphénytoïne, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. (notice Halobétasol, Mises en garde et précautions)

Caution is advised when haloperidol decanoate is used in combination with drugs known to cause electrolyte imbalance (e.g., diuretics or corticosteroids) because hypokalemia, hypomagnesemia, and hypocalcemia are risk factors for QT prolongation. (notice Halopéridol, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Long-term treatment with steroids may be necessary (see PRECAUTIONS, Laboratory Tests ). (notice Hydralazine, Mises en garde)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et chlorphénamine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et homatropine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et ibuprofène, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydrocodone et paracétamol, Mises en garde)

Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. (notice Fludrocortisone, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Hydromorphone, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Ibuprofène et famotidine, Mises en garde et précautions)

If either is abnormal, consider prophylactic use of systemic steroids (1-2 mg/kg) for one to two weeks concomitantly with Gleevec at the initiation of therapy. (notice Imatinib, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Indométacine, Mises en garde et précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Although other risk factors were present in some cases (such as corticosteroid use and/or exposure to radiation), a possible risk attributable to KALYDECO cannot be excluded. (notice Ivacaftor, Mises en garde et précautions)

Oral hydration, recumbency, intravenous normal saline, and/or parenteral corticosteroids have been used to treat postural hypotension. (notice Ivermectine, Mises en garde)

PRECAUTIONS General Ketoprofen Capsules, USP cannot be expected to substitute for corticosteroids or to treat corticosteroid insufficiency. (notice Kétoprofène, Mises en garde et précautions)

In addition to past history of ulcer disease, other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids, or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Kétorolac, Mises en garde et précautions)

Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone ↑ corticosteroids (systemic) Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. (notice Lénacapavir, Interactions médicamenteuses)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients usually over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Lévofloxacine, Mises en garde et précautions)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Lévorphanol, Mises en garde)

If the patient needs more doses of XOPENEX HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Lévosalbutamol, Mises en garde et précautions)

Failure to do so may precipitate an acute adrenal crisis when thyroid hormone therapy is initiated, due to increased metabolic clearance of glucocorticoids by thyroid hormone. (notice Lévothyroxine, Mises en garde et précautions)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (notice Lévothyroxine et liothyronine, Précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Acute Adrenal Crisis in Patients with Concomitant Adrenal Insufficiency Thyroid hormone increases metabolic clearance of glucocorticoids. (notice Liothyronine, Mises en garde et précautions)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

…Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↓ lopinavir ↑ glucocorticoids Coadministration with oral dexamethasone or other systemic corticosteroids that induce CYP3A may result in loss of therapeutic effect and development of resistance to lopinavir. (notice Lopinavir et ritonavir, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (notice Margétuximab, Mises en garde et précautions)

MPA Injectable Suspension, USP can pose an additional risk in patients with risk factors for osteoporosis (e.g., metabolic bone disease, chronic alcohol and/or tobacco use, anorexia nervosa, strong family history of osteoporosis or chronic use of drugs that can reduce bone mass such as anticonvulsants or corticosteroids). (notice Médroxyprogestérone, Mises en garde et précautions)

Laboratory evaluation for adrenal insufficiency and consideration of replacement or stress doses of a rapidly acting glucocorticoid are strongly recommended in such patients. (notice Mégestrol, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Méloxicam, Mises en garde et précautions)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Decrease corticosteroids gradually, if appropriate. (notice Mépolizumab, Mises en garde et précautions)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Méthadone, Mises en garde et précautions)

Drug Interactions Methazolamide should be used with caution in patients on steroid therapy because of the potential for developing hypokalemia. (notice Méthazolamide, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

If not, corticosteroids may be given and other causes of anemia should be considered. (notice Méthyldopa, Mises en garde)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

This can be corrected by giving appropriate doses of corticosteroids. (notice Métyrapone, Mises en garde et précautions)

The potential for supine hypertension should be carefully monitored in these patients and may be minimized by either reducing the dose of fludrocortisone acetate or decreasing the salt intake prior to initiation of treatment with midodrine hydrochloride. (notice Midodrine, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Although ASMANEX HFA may improve control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of corticosteroid systemically and does NOT provide the mineralocorticoid activity necessary for coping with these emergencies. (notice Mométasone, Mises en garde et précautions)

Inhaled corticosteroid may be reduced gradually. (notice Montélukast, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Morphine, Mises en garde et précautions)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in patients taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Moxifloxacine, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Nabumétone, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Nalbuphine, Mises en garde)

…hypoglycemia concomitant administration of medications that may lower the seizure threshold, including other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, systemic steroids Recommendations for Reducing the Risk of Seizure: Clinical experience with bupropion suggests that the risk of seizure may be minimized by adhering to the recommended… (notice Naltrexone et bupropion, Mises en garde et précautions)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène, Mises en garde et précautions)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Naproxène et ésoméprazole, Mises en garde et précautions)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Use OFEV with caution when treating patients with recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. (notice Nintédanib, Mises en garde et précautions)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

Estrogen —increased levels of corticosteroid-binding globulin thereby increasing the bound (inactive) fraction; this effect is at least balanced by decreased metabolism of corticosteroids. (notice Fludrocortisone, Interactions médicamenteuses)

The risk of developing fluoroquinolone-associated tendinitis and tendon rupture is increased in patients over 60 years of age, in those taking corticosteroid drugs, and in patients with kidney, heart or lung transplants. (notice Ofloxacine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Olicéridine, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Corticosteroid Reduction: Do not abruptly discontinue corticosteroids upon initiation of OMLYCLO therapy. (notice Omalizumab, Mises en garde et précautions)

Aspirin — increased ulcerogenic effect; decreased pharmacologic effect of aspirin. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Oxaprozine, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxycodone et paracétamol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Oxymorphone, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Paracétamol et codéine, Mises en garde)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy, concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Paracétamol et ibuprofène, Mises en garde et précautions)

If adrenal insufficiency is suspected, it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses . (notice Pasiréotide, Mises en garde et précautions)

Treatment has consisted of high doses of corticosteroids alone or, in some cases, concomitantly with an immunosuppressant. (notice Pénicillamine, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Pentazocine et naloxone, Mises en garde)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Péthidine, Mises en garde et précautions)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

Use of corticosteroids may cause a protein catabolic state and, thereby, potentially increase plasma ammonia levels in patients with impaired ability to form urea. (notice Phénylacétate de sodium et benzoate de sodium, Interactions médicamenteuses)

Corticosteroids, valproic acid, or haloperidol : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de glycérol, Interactions médicamenteuses)

Valproic Acid, Haloperidol, or Corticosteroids : May increase plasma ammonia level; monitor ammonia levels closely. (notice Phénylbutyrate de sodium, Interactions médicamenteuses)

Agonistic Effects (increase in BIORPHEN blood pressure effect) can occur with monoamine oxidase inhibitors (MAOI), oxytocin and oxytocic drugs, tricyclic antidepressants, angiotensin and aldosterone, atropine, steroids, norepinephrine transporter inhibitors, ergot alkaloids. (notice Phényléphrine, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk of GI bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, antiplatelet drugs (such as aspirin), anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Piroxicam, Mises en garde et précautions)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Prométhazine et codéine, Mises en garde et précautions)

The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high-dose infusions of propofol (> 5 mg/kg/hour for > 48 hours). (notice Propofol, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor serum potassium levels; use potassium supplements if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Barbiturates, phenytoin, or rifampin —increased metabolic clearance of fludrocortisone acetate because of the induction of hepatic enzymes. (notice Fludrocortisone, Interactions médicamenteuses)

…Haloperidol Barbiturates Phenobarbital Benzodiazepines Diazepam Beta-Blockers Propranolol Calcium Channel Blockers Diltiazem, nifedipine, verapamil Cardiac Glycoside Preparations Digoxin Corticosteroids Prednisone Fibrates Clofibrate Oral Hypoglycemics Sulfonylureas (e.g., glyburide, glipizide) Hormonal Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants… (notice Rifapentine, Interactions médicamenteuses)

Systemic/Inhaled/ Nasal/Ophthalmic Corticosteroids: e.g., betamethasone budesonide ciclesonide dexamethasone fluticasone methylprednisolone mometasone prednisone triamcinolone ↑ glucocorticoids Coadministration with corticosteroids whose exposures are significantly increased by strong CYP3A inhibitors can increase the risk for Cushing’s syndrome and adrenal suppression.Alternative… (notice Ritonavir, Interactions médicamenteuses)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Therefore, for patients receiving both neuromuscular blocking agents (including Rocuronium Bromide Injection) and corticosteroids, the period of use of the neuromuscular blocking agent should be limited as much as possible and only used in the setting where in the opinion of the prescribing physician, the specific advantages of the drug outweigh the risk. (notice Rocuronium, Mises en garde et précautions)

If the patient needs more doses of Albuterol Sulfate HFA than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Salbutamol, Mises en garde et précautions)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Rarely salicylate toxicity may occur in patients who discontinue steroids after concurrent high-dose aspirin therapy. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Sulindac, Mises en garde)

Other factors that increase the risk for gastrointestinal bleeding in patients treated with NSAIDs include longer duration of NSAID therapy; concomitant use of oral corticosteroids, aspirin, anticoagulants, or selective serotonin reuptake inhibitors (SSRIs); smoking; use of alcohol; older age; and poor general health status. (notice Sumatriptan et naproxène, Mises en garde et précautions)

The neuromuscular blocking effect of succinylcholine may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase [see Warnings and Precautions (5.9) ]. (notice Suxaméthonium, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tapentadol, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (notice Témozolomide, Mises en garde et précautions)

If ILD is suspected, discontinue TORISEL, and consider use of corticosteroids and/or antibiotics. (notice Temsirolimus, Mises en garde et précautions)

If the patient needs more doses of terbutaline sulfate tablets than usual, this may be a marker of destabilization of asthma and requires reevaluation of the patient and the treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids. (notice Terbutaline, Mises en garde)

Risk factors for development of calciphylaxis include underlying auto-immune disease, kidney failure, and concomitant warfarin or systemic corticosteroid use. (notice Tériparatide, Mises en garde et précautions)

Glucocorticoids : Patients receiving glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in maintenance or stress doses following initiation of EGRIFTA SV. (notice Tésamoréline, Interactions médicamenteuses)

Anabolic steroids (particularly C-17 alkylated androgens such as oxymetholone, methandrostenolone, norethandrolone, and similar compounds)—enhanced tendency toward edema. (notice Fludrocortisone, Interactions médicamenteuses)

Dosage Increases: Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic lung disease since theophylline provides little added benefit to inhaled beta2 -selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. (notice Théophylline, Mises en garde)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (notice Tiotropium, Interactions médicamenteuses)

Monitor for symptoms of hyperglycemia; adjust dosage of antidiabetic drug upward if necessary. (notice Fludrocortisone, Interactions médicamenteuses)

Other factors that increase the risk for GI bleeding in patients treated with NSAIDs include concomitant use of oral corticosteroids or anticoagulants, longer duration of NSAID therapy, smoking, use of alcohol, older age, and poor general health status. (notice Tolmétine, Mises en garde)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol, Mises en garde et précautions)

If adrenal insufficiency is diagnosed, treat with physiologic replacement doses of corticosteroids. (notice Tramadol et paracétamol, Mises en garde et précautions)

Interrupt TRAZIMERA infusion in all patients experiencing dyspnea, clinically significant hypotension, and intervention of medical therapy administered (which may include epinephrine, corticosteroids, diphenhydramine, bronchodilators, and oxygen). (notice Trastuzumab, Mises en garde et précautions)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

Amphotericin B or potassium-depleting diuretics (benzothiadiazines and related drugs, ethacrynic acid and furosemide)—enhanced hypokalemia. (notice Fludrocortisone, Interactions médicamenteuses)

• Adrenal Dysfunction : Carefully monitor patients receiving voriconazole and corticosteroids (via all routes of administration) for adrenal dysfunction both during and after voriconazole treatment. (notice Voriconazole, Mises en garde et précautions)

Oral anticoagulants — decreased prothrombin time response. (notice Fludrocortisone, Interactions médicamenteuses)

Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (notice Zénocutuzumab, Mises en garde et précautions)

Tendon rupture may occur more frequently in patients over 60 years of age, in those taking corticosteroid or fluoroquinolone drugs, in patients with renal failure, and in patients with previous tendon disorders. (notice Acide bempédoïque, Mises en garde et précautions)

If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (notice Altéplase, Mises en garde et précautions)

Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids [see Adverse Reactions (6.1) ] . (notice Amikacine, Mises en garde et précautions)

Antithyroid drugs, β-adrenergic blockers, temporary corticosteroid therapy may be necessary to treat the symptoms of hyperthyroidism. (notice Amiodarone, Mises en garde et précautions)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine, Interactions médicamenteuses)

Interference with Laboratory Tests Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Amphétamine et dexamfétamine, Interactions médicamenteuses)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Ampicilline, Mises en garde)

Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (notice Bévacizumab, Mises en garde et précautions)

The administration of corticosteroids has been suggested, but the results have not been impressive or uniformly successful. (notice Busulfan, Mises en garde)

Corticosteroids A relationship of functional antagonism exists between vitamin D analogues, which promote calcium absorption, and corticosteroids, which inhibit calcium absorption. (notice Calcitriol, Interactions médicamenteuses)

Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (notice Cannabidiol (sur ordonnance), Mises en garde et précautions)

…clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral… (notice Carbamazépine, Interactions médicamenteuses)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfaclor, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfadroxil, Mises en garde et précautions)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefdinir, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Céfotétan, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Cefprozil, Mises en garde)

SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (notice Ceftazidime, Mises en garde)

Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (notice Ceftriaxone, Mises en garde et précautions)

The use of prophylactic steroids (e.g., 100 mg/m 2 hydrocortisone on Days 1 through 3) may be of benefit in preventing signs or symptoms of SIRS or capillary leak syndrome. (notice Clofarabine, Mises en garde et précautions)

Elevated urinary steroid levels, varying degrees of electrolyte imbalance, hypovolemia, hemoconcentration, and hypoproteinemia may occur. (notice Clomifène, Mises en garde)

The recovery of the adrenal gland may take from days to months so patients should be protected from the stress (e.g., trauma or surgery) by the use of corticosteroids during the period of stress. (notice Corticotropine, Mises en garde et précautions)

Fluid retention events were typically managed by supportive care measures that may include diuretics or short courses of steroids. (notice Dasatinib, Mises en garde et précautions)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Dexamfétamine, Interactions médicamenteuses)

These would include diuretics, laxatives and supraphysiological use of steroid hormones with mineralocorticoid potential. (notice Dropéridol, Interactions médicamenteuses)

Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (notice Éfavirenz, Mises en garde et précautions)

Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (notice Éfavirenz, lamivudine et ténofovir, Mises en garde et précautions)

Steroids may or may not be effective in controlling these hemolytic episodes. (notice Fludarabine, Mises en garde et précautions)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Fluoxétine, Mises en garde et précautions)

In the reported cases NME resolved with discontinuation of the glucagon, and treatment with corticosteroids was not effective. (notice Glucagon, Mises en garde et précautions)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (notice Ipratropium, Interactions médicamenteuses)

Patients with Grade 1 and 2 TFR may also be treated with corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or narcotic analgesics for management of TFR symptoms. (notice Lénalidomide, Mises en garde et précautions)

The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (notice Melphalan, Mises en garde)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (notice Méthamphétamine, Interactions médicamenteuses)

Following concurrent administration of mitoxantrone injection with corticosteroids, no evidence of drug interactions has been observed. (notice Mitoxantrone, Interactions médicamenteuses)

Both cases required hospitalization, and resolved after treatment with antibiotics and corticosteroids. (notice Naltrexone, Mises en garde et précautions)

Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (notice Olanzapine et fluoxétine, Mises en garde et précautions)

If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (notice Oxacilline, Mises en garde)

Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (notice Pénicilline G, Mises en garde)

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. (notice Pénicilline V, Mises en garde)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (notice Prednisolone, Mises en garde et précautions)

Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. (notice Prednisone, Mises en garde et précautions)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Propylthiouracile, Mises en garde)

Drug/Laboratory Interactions Quinine may produce an elevated value for urinary 17-ketogenic steroids when the Zimmerman method is used. (notice Quinine, Interactions médicamenteuses)

Other Concomitant Medications EVISTA can be concomitantly administered with ampicillin, amoxicillin, antacids, corticosteroids, and digoxin [see Clinical Pharmacology ( 12.3 )] . (notice Raloxifène, Interactions médicamenteuses)

If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (notice Ténectéplase, Mises en garde et précautions)

In some cases, vasculitis resolved/improved with drug discontinuation; however, more severe cases required treatment with additional measures including corticosteroids, immunosuppressant therapy, and plasmapheresis. (notice Thiamazole, Mises en garde)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (notice Tobramycine, Interactions médicamenteuses)

Les corticoïdes tels que la prednisone réduisent l'absorption du calcium et perturbent le métabolisme de la vitamine D, ce qui contribue à la perte osseuse. (NIH Office of Dietary Supplements, Vitamin D)

Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (notice Ziprasidone, Mises en garde et précautions)